Korro Bio receives HREC approval, CTN clearance to initiate Phase 1/2a study

Korro Bio (KRRO) announced that it has received approval from the Australian Bellberry Human Research Ethics Committee, HREC, and clearance from the Australian Therapeutic Goods Administration, TGA, to initiate a Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency, AATD. “We are thrilled to receive approval to proceed with our clinical study in Australia,” said Kemi Olugemo, MD, Chief Medical Officer at Korro. “Multiple dose treatment with KRRO-110 in a human transgenic mouse model of PiZZ genotype achieved greater than 60% editing and resulted in secretion of functional M-AAT at therapeutically relevant levels. This approval allows us to demonstrate the potential of KRRO-110 in patients with the PiZZ genotype who remain at risk for serious lung and liver complications despite receiving standard-of-care treatment.”